Navigation Links
Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
Date:12/7/2007

World Congress on Osteoarthritis in Fort Lauderdale, Florida.

This press release contains "forward-looking" statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. Acologix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Acologix' business.


'/>"/>
SOURCE Acologix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...ed study will enroll newly diagnosed, elderly AML ...wswire/ -- Celator Pharmaceuticals today announced...omized Phase 2 clinical study of CPX-351 (Cytarabi...th newly diagnosed acute myeloid leukemia (AML). ,...eldman, MD at the Weill Medical College of Cornel...
(Date:11/13/2008)...Study Suggests Nutritional Supplements Prior to Su...re-USNewswire/ -- Identifying,malnutrition before ...dy,contouring will significantly decrease surgical...scar quality and boost patient energy levels,acco...and Reconstructive,Surgery(R), the official medica...
(Date:11/12/2008)...YORK, Nov. 12 A new stu... of Cell will help answer the,question, what cause...questions in the medical research into,Parkinson,s... brain to die,in the first place. Answering this q...e are two nearly identical types of brain cells th...
(Date:11/12/2008)...ELAND, Ohio and LOD, Israel, November 12 /PRNewswi...ical Center, NY indicated that,patient-specific CT...or,(ANGIO Mentor(TM), Simbionix US) with high face... simulation improved the operative flow,increased...decreased,overall operative and fluoroscopy time a...
Breaking Medicine Technology:Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2A Window Into Parkinson's Disease 2Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4902 1Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4902 2Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4902 3Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4902 4Cynosure Introduces Smartlipo MPX 28TM 29 Dual Wavelength Workstation for LaserBodySculpting 28SM 29 4900 1Cynosure Introduces Smartlipo MPX 28TM 29 Dual Wavelength Workstation for LaserBodySculpting 28SM 29 4900 2Cynosure Introduces Smartlipo MPX 28TM 29 Dual Wavelength Workstation for LaserBodySculpting 28SM 29 4900 3Cynosure Introduces Smartlipo MPX 28TM 29 Dual Wavelength Workstation for LaserBodySculpting 28SM 29 4900 4Cynosure Introduces Smartlipo MPX 28TM 29 Dual Wavelength Workstation for LaserBodySculpting 28SM 29 4900 5Alfacell Announces Retirement of Chief Executive Officer 4898 1Alfacell Announces Retirement of Chief Executive Officer 4898 2Alfacell Announces Retirement of Chief Executive Officer 4898 3Alfacell Announces Retirement of Chief Executive Officer 4898 4Neuralstem Announces Issuance of Core Technology Patent in Europe 1912 1Neuralstem Announces Issuance of Core Technology Patent in Europe 1912 2
...ans 350,000 Locations Across the Genome From 242,P...te to Acute,Lymphoblastic Leukemia, Suggesting New...ch 07, 2007 /PRNewswire/ -- Investigators at,St. J...reviously,unsuspected mutations that contribute to...ukemia (ALL), the most common cancer in,children. ...
... PARK, N.C., Mar 8, 2007 (CCNMatthews via COMTEX,N...)(AMEX:ADH), a,biopharmaceutical company with a br...nt, today announced that Dr. Antonella,Perotti, MD...dation, an investigator in Adherex,s European Phas...data today from that study at,the 5th Internationa...
Other Medicine Technology:Major Gene Study Uncovers Secrets of Leukemia 2Major Gene Study Uncovers Secrets of Leukemia 3Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies 2Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies 3
(Date:11/21/2008)... 11.4% Shareholders Intend To Vigorously Protect ... CINCINNATI, Nov. 21 D...ay filed an amendment to their Schedule 13D with t...roup previously filed a 13D disclosing ownership o...ch operates 77 LasikPlus fixed-site laser vision c...
(Date:11/21/2008)... NEW YORK, Nov. 21 The general me...voted to induct three new individuals at their Ann... the Pierre hotel in New York. A,Lifetime Achieve...nductees into the Medical Advertising Hall of Fame...ing career with an account position,at Sudler &am...
(Date:11/21/2008)... MONTVALE, N.J., Nov. 21 /PRNewswire-FirstCall/ -...announced that its shareholders overwhelmingly app...the acquisition of Barr by Teva Pharmaceuticals In...y,s vote demonstrated the overwhelming support of ...uce L. Downey, Barr,s Chairman and CEO. "We are pl...
(Date:11/21/2008)... Experiments in mice find running increases produ...ov. 21 (HealthDay News) -- In experiments in mice,...oduction of brain stem cells usually seen with agi...able restoration of the brain,s ability to stave o...o restore a neurochemical that is essential for th...
Breaking Medicine News(10 mins):Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Exercise Keeps the Brain Young 2
...rs of the Holocaust are more likely to suffer from...ne Raviv and his colleagues at Israel's //Haifa Un...ed by the near-starvation of European Jews during ...ers looked at the incidence and death rate from ca...
...tors in Toronto are desperately trying to reattach... his foot in a freak accident that involved his fa...g to York Region police the boys father had been r...p unexpectedly behind him. Constable Laurie Perks ...
... University researchers plan to ask women to donat...ryonic stem cells matched to patients // which the... debilitating diseases such as diabates or neurode...ract embryonic stem (ES) cells after creating huma...
...research has revealed that taking antibiotics for ...to 10 days is equally effective in the treatment o...this could also help to curb the rising problem of...ria, Lead researcher Dr. Jan M Prins, an internis...
Other Medicine News:Health News:Pneumonia Effectively Treated with Short-Term Antibiotic Course 2
...ons stand alone. It can also be installed as part ...a management system which can be used in ophthalmi...us, retinal surgeries are supported through the mo...per charts. They are supported on tablet PC techno...
...n a powerful, easy-to-use medical practice design ...and business requirements and situations of an oph...rovide patient care assistance as well as ensure d... for Eye's simple "point and click" or touch scree...
...ion to assist you in managing your optometric prac...hrough the creative use of technology. No more nee...waiting to see the doctor. No more wasting time se... handwriting on all paperwork. Give your administr...
...c Medical Office (EMO) for the Optometry specialis...n addition to retrieving and storing your charts e...e patient office flow including documentation of p... billing information. ChartLogic also gives you da...
Medicine Products: